bs-4841R [Primary Antibody]
TACI Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TACI

Immunogen Range: 21-120/293


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human TNFRSF13B/TACI

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

TACI is a lymphocyte specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein binds to both APRIL and BAFF and induces activation of the transcription factors NFAT (nuclear-factor of activated T cells), AP1, and NF kappa B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith Magenis syndrome region on chromosome 17.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 32


Cross Reactive Species: Mouse

Predicted Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Sen Luo. et al. Three-gene signature revealing the dynamics of lymphocyte infiltration in subchondral bone during osteoarthritis progression. INT IMMUNOPHARMACOL. 2024 Aug;137:112431Read more>>
VALIDATION IMAGES

Mouse spleen lysates probed with TACI Polyclonal Antibody, Unconjugated (bs-4841R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Mouse Stomach tissue lysates; Lane 2: Mouse Lung tissue lysates probed with TACI Polyclonal Antibody, Unconjugated (bs-4841R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.